Home / Drugs & Interventions / Brexanolone / History Brexanolone History and Updates 37 events · 2018 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 12, 2026 .
Brexanolone — history and updates FDA approvals, label revisions, recalls, trials, and pivotal publications FDA approvals Label revisions Recalls + safety Trials Publications 2019 2020 2021 2022 2023 2024 2025 2026 2027 Trial: NCT06580444
2025-07-28 → 2027-02-26 (primary completion) Trial: NCT05223829
2023-08-01 → 2025-12-31 (primary completion) Trial: NCT05254405
2023-06-01 → 2025-12-30 (primary completion) Trial: NCT05645432
2023-05-10 → 2023-11-21 (primary completion) Trial: NCT05329779
2022-11-04 → 2023-07-18 (primary completion) Trial: NCT05543746
2022-08-05 → 2023-11-15 (primary completion) Trial: NCT05314153
2022-02-23 → 2024-06-01 (primary completion) Trial: NCT04537806
2020-12-18 → 2021-07-01 (primary completion) Trial: NCT04273191
2020-02-29 → 2021-08-31 (primary completion) Trial: NCT03665038
2018-09-07 → 2021-01-08 (primary completion) Results posted — 2022-07-27
Trial results posted: NCT04537806
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19) Results posted — 2022-08-11
Trial results posted: NCT03665038
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) Results posted — 2024-12-12
Trial results posted: NCT05645432
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus Results posted — 2025-01-28
Trial results posted: NCT05543746
Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression Results posted — 2026-01-22
Trial results posted: NCT05329779
Study on Allopregnanolone and Depression in Perimenopausal Women today (2026-05-25) FDA approval Label revision Recall or safety Trial activity Pivotal publication Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-05-25 Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Brexanolone since 2018, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (1) Upcoming & expected milestones Primary completion Feb 26, 2027 · ClinicalTrials.gov
Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Past events 2026
Results posted Jan 22, 2026 · ClinicalTrials.gov
Study on Allopregnanolone and Depression in Perimenopausal Women
2025
Primary completion Dec 31, 2025 · ClinicalTrials.gov
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
Primary completion Dec 30, 2025 · ClinicalTrials.gov
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
Primary completion Dec 1, 2025 · ClinicalTrials.gov
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
Trial started Jul 28, 2025 · ClinicalTrials.gov
Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Results posted Jan 28, 2025 · ClinicalTrials.gov
Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
2024
Results posted Dec 12, 2024 · ClinicalTrials.gov
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Trial registered Aug 30, 2024 · ClinicalTrials.gov
Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Primary completion Jun 1, 2024 · ClinicalTrials.gov
Effects Zulresso on Postpartum Psychosis
2023
Primary completion Nov 21, 2023 · ClinicalTrials.gov
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Primary completion Nov 15, 2023 · ClinicalTrials.gov
Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
Trial started Aug 1, 2023 · ClinicalTrials.gov
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
Primary completion Jul 18, 2023 · ClinicalTrials.gov
Study on Allopregnanolone and Depression in Perimenopausal Women
Trial started Jun 1, 2023 · ClinicalTrials.gov
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
Trial started May 10, 2023 · ClinicalTrials.gov
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
2022
Trial registered Dec 9, 2022 · ClinicalTrials.gov
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Trial started Nov 4, 2022 · ClinicalTrials.gov
Study on Allopregnanolone and Depression in Perimenopausal Women
Trial registered Sep 16, 2022 · ClinicalTrials.gov
Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
Results posted Aug 11, 2022 · ClinicalTrials.gov
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Trial started Aug 5, 2022 · ClinicalTrials.gov
Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
Results posted Jul 27, 2022 · ClinicalTrials.gov
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Trial registered Apr 15, 2022 · ClinicalTrials.gov
Study on Allopregnanolone and Depression in Perimenopausal Women
Trial registered Apr 6, 2022 · ClinicalTrials.gov
Effects Zulresso on Postpartum Psychosis
Trial registered Feb 24, 2022 · ClinicalTrials.gov
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
Trial started Feb 23, 2022 · ClinicalTrials.gov
Effects Zulresso on Postpartum Psychosis
Trial registered Feb 4, 2022 · ClinicalTrials.gov
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
2021
Primary completion Aug 31, 2021 · ClinicalTrials.gov
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
Primary completion Jul 1, 2021 · ClinicalTrials.gov
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Primary completion Jan 8, 2021 · ClinicalTrials.gov
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
2020
Trial started Dec 18, 2020 · ClinicalTrials.gov
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Trial registered Sep 3, 2020 · ClinicalTrials.gov
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Trial started Feb 29, 2020 · ClinicalTrials.gov
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
Trial registered Feb 18, 2020 · ClinicalTrials.gov
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
2019
Trial registered Apr 23, 2019 · ClinicalTrials.gov
Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression
2018
Trial registered Sep 11, 2018 · ClinicalTrials.gov
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Trial started Sep 7, 2018 · ClinicalTrials.gov
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Sources FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed , filtered to high-impact journals linked to a Phase 3 trial in our inventory.